Literature DB >> 22230156

Percutaneous edge-to-edge mitral valve repair in high-surgical-risk patients: do we hit the target?

Ben J L Van den Branden1, Martin J Swaans, Martijn C Post, Benno J W M Rensing, Frank D Eefting, Wybren Jaarsma, Jan A S Van der Heyden.   

Abstract

OBJECTIVES: This study sought to assess the feasibility and safety of percutaneous edge-to-edge mitral valve (MV) repair in patients with an unacceptably high operative risk.
BACKGROUND: MV repair for mitral regurgitation (MR) can be accomplished by use of a clip that approximates the free edges of the mitral leaflets.
METHODS: All patients were declined for surgery because of a high logistic EuroSCORE (>20%) or the presence of other specific surgical risk factors. Transthoracic echocardiography was performed before and 6 months after the procedure. Differences in New York Heart Association (NYHA) functional class, quality of life (QoL) using the Minnesota questionnaire, and 6-min walk test (6-MWT) distances were reported.
RESULTS: Fifty-five procedures were performed in 52 patients (69.2% male, age 73.2 ± 10.1 years, logistic EuroSCORE 27.1 ± 17.0%). In 3 patients, partial clip detachment occurred; a second clip was placed successfully. One patient experienced cardiac tamponade. Two patients developed inguinal bleeding, of whom 1 needed surgery. Six patients (11.5%) died during 6-month follow-up (5 patients as a result of progressive heart failure and 1 noncardiac death). The MR grade before repair was ≥3 in 100%; after 6 months, a reduction in MR grade to ≤2 was present in 79% of the patients. Left ventricular (LV) end-diastolic diameter, LV ejection fraction, and systolic pulmonary artery pressure improved significantly. Accompanied improvements in NYHA functional class, QoL index, 6-MWT distances, and log N-terminal pro-B-type natriuretic peptide were observed.
CONCLUSIONS: In a high-risk population, MR reduction can be achieved by percutaneous edge-to-edge valve repair, resulting in LV remodeling with improvement of functional capacity after 6 months.
Copyright © 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22230156     DOI: 10.1016/j.jcin.2011.09.013

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  10 in total

Review 1.  Estrogens, progestins, menopause and neurodegeneration: basic and clinical studies.

Authors:  J W Simpkins; S-H Yang; Y Wen; M Singh
Journal:  Cell Mol Life Sci       Date:  2005-02       Impact factor: 9.261

Review 2.  Mitral regurgitation in patients with heart failure. Interventional therapies.

Authors:  V Rudolph; S Baldus
Journal:  Herz       Date:  2013-03       Impact factor: 1.443

Review 3.  Mortality after percutaneous edge-to-edge mitral valve repair: a contemporary review.

Authors:  Friso A Kortlandt; Thomas de Beenhouwer; Martin J Swaans; Marco C Post; Jan A S van der Heyden; Frank D Eefting; Benno J W M Rensing
Journal:  Cardiovasc Diagn Ther       Date:  2016-04

Review 4.  Functional status and quality of life after transcatheter mitral valve repair: a prospective cohort study and systematic review.

Authors:  Christos Iliadis; Samuel Lee; Kathrin Kuhr; Clemens Metze; Anna-Sophie Matzik; Guido Michels; Volker Rudolph; Stephan Baldus; Roman Pfister
Journal:  Clin Res Cardiol       Date:  2017-08-07       Impact factor: 5.460

Review 5.  Mitral regurgitation. Timing of surgery or interventional treatment.

Authors:  A Vahanian; B Iung
Journal:  Herz       Date:  2016-02       Impact factor: 1.443

Review 6.  Mitral Valve Interventions in Structural Heart Disease.

Authors:  Matteo Saccocci; Maurizio Taramasso; Francesco Maisano
Journal:  Curr Cardiol Rep       Date:  2018-05-17       Impact factor: 2.931

7.  Position Statement of the Brazilian Cardiology Society and the Brazilian Society of Hemodynamics and Interventional Cardiology on Training Centers and Professional Certification in Hemodynamics and Interventional Cardiology - 2020.

Authors:  José Airton de Arruda; Viviana de Mello Guzzo Lemke; José Mariani Júnior; Adriano Henrique Pereira Barbosa; Alexandre Schaan de Quadros; Carlos Augusto Cardoso Pedra; Cristiano de Oliveira Cardoso; Ênio Eduardo Guérios; Henrique Barbosa Ribeiro; Luiz Antonio Gubolino; Maurício Cavalieri Machado; Mauricio Jaramillo Hincapie; Nelson Antonio Moura de Araujo; Raul Ivo Rossi Filho; Ricardo Alves da Costa; Silvio Gioppato
Journal:  Arq Bras Cardiol       Date:  2020-01       Impact factor: 2.000

8.  Current MitraClip experience, safety and feasibility in the Netherlands.

Authors:  Z Rahhab; F A Kortlandt; J F Velu; R A J Schurer; V Delgado; P Tonino; A J Boven; B J L Van den Branden; A O Kraaijeveld; M Voskuil; J Hoorntje; M van Wely; K van Houwelingen; G B Bleeker; B Rensing; I Kardys; J Baan; J A S Van der Heyden; N M Van Mieghem
Journal:  Neth Heart J       Date:  2017-06       Impact factor: 2.380

9.  The predictive value of conventional surgical risk scores for periprocedural mortality in percutaneous mitral valve repair.

Authors:  F A Kortlandt; C C van 't Klooster; A L M Bakker; M J Swaans; J C Kelder; T L de Kroon; B J W M Rensing; F D Eefting; J A S van der Heyden; M C Post
Journal:  Neth Heart J       Date:  2016-07       Impact factor: 2.380

Review 10.  Mitral valve repair.

Authors:  Alberto Pozzoli; Michele De Bonis; Ottavio Alfieri
Journal:  F1000Res       Date:  2016-06-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.